Melphalan
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Melphalan: From Multiple Myeloma to Gonadal Germ Cell Tumor
One-Sentence Summary
Melphalan (DrugBank DB01042) is a classic alkylating chemotherapy agent originally established for multiple myeloma and as a high-dose conditioning agent before autologous stem cell transplant. The TxGNN model predicts it may be effective for Gonadal Germ Cell Tumor, with 8 clinical trials and 4 publications currently supporting this direction.
Note: The evidence pack's structured original_indications field and MOA field are both empty/data-gap; the original-indication context above is drawn from established public drug knowledge (DrugBank), not from this Evidence Pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack (taiwan_regulatory.licenses empty); commonly known indication is Multiple Myeloma |
| Predicted New Indication | Gonadal Germ Cell Tumor |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 (multiple completed early-phase clinical trials + supporting literature, no completed Phase 3 RCT) |
| New Zealand Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack (MOA = Data Gap, severity: High). Based on generally known pharmacology, melphalan is a bifunctional alkylating agent (a phenylalanine derivative of nitrogen mustard) that cross-links DNA strands, causing strand breaks and apoptosis in rapidly dividing cells. This mechanism underlies its established use in multiple myeloma and as a high-dose conditioning agent prior to autologous hematopoietic stem cell transplantation (ASCT).
The link to gonadal germ cell tumor is directly supported by the trial evidence itself: melphalan already appears as a component of high-dose salvage chemotherapy regimens for relapsed/refractory germ-cell tumors — for example NCT00936936 combines melphalan with gemcitabine, docetaxel, and carboplatin as part of a two-cycle high-dose regimen with stem cell rescue, and NCT00638898 pairs melphalan with busulfan and topotecan for the same purpose. Germ cell tumors are highly chemosensitive, and high-dose alkylator-based regimens with ASCT support are an established salvage strategy in this population, which is mechanistically consistent with melphalan's cytotoxic, DNA-damaging activity.
Because these are largely single-arm, dose-finding, or pilot studies rather than randomized controlled trials, the mechanistic plausibility is well supported but the confirmatory efficacy evidence remains at an early/observational stage.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002750 | Phase 1 | Completed | 6 | Intrathecal melphalan for recurrent/persistent neoplastic meningitis |
| NCT00936936 | Phase 2 | Completed | 64 | Two-cycle high-dose chemo (gemcitabine/docetaxel/melphalan/carboplatin, then ifosfamide/carboplatin/etoposide) for poor-prognosis relapsed germ-cell tumors |
| NCT01272817 | N/A | Completed | 36 | Nonmyeloablative allogeneic HSCT using melphalan+cladribine or TLI conditioning across various malignancies including germ-cell-relevant settings |
| NCT00638898 | Phase 1 | Completed | 25 | High-dose busulfan/melphalan/topotecan followed by autologous HSCT in advanced/recurrent tumors |
| NCT00060255 | Phase 2 | Completed | 451 | Eight high-dose chemo regimens ± TBI before autologous transplant in hematologic and selected solid tumors |
| NCT00003425 | Phase 1/2 | Completed | 25 | Escalating-dose melphalan with autologous stem cell support and amifostine cytoprotection in cancer patients |
| NCT00003926 | Phase 1 | Terminated | 13 | Amifostine chemoprotection with autologous stem cell transplant for high-risk/relapsed pediatric solid and brain tumors |
| NCT00536601 | N/A | Completed | 174 | High-dose regimens ± TBI before autologous transplant in hematologic malignancies and selected solid tumors |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 4270380 | 1973 | Pending classification | Oncology | Chemotherapy of testicular germinal tumors (abstract not available in Evidence Pack) |
| 24913 | 1977 | Pending classification | The Urologic Clinics of North America | Seminoma review (abstract not available) |
| 13392619 | 1956 | Pending classification | Voprosy Onkologii | Experience treating testicular seminoma and metastases with sarcolysin (melphalan) (abstract not available) |
| 14151951 | 1964 | Pending classification | Acta - Unio Internationalis Contra Cancrum | Influence of hormonal and alkylating drugs on pituitary follicle-stimulating function (abstract not available) |
New Zealand Market Information
Melphalan is currently not marketed in New Zealand (0 authorizations on file in this Evidence Pack).
Cytotoxicity
Melphalan is a classic conventional cytotoxic chemotherapy agent (alkylating agent, nitrogen mustard class), meeting the antineoplastic criteria used for this section.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Alkylating agent — nitrogen mustard class) |
| Myelosuppression Risk | High — myelosuppression is the well-recognized dose-limiting toxicity of melphalan; specific institutional toxicity data not available in this Evidence Pack |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential, platelet count, renal function; specific monitoring protocol not available in this Evidence Pack |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed early-phase clinical trials (8 total) show melphalan already used as a component of high-dose salvage regimens for relapsed/refractory germ-cell tumors, consistent with the drug's established chemosensitivity profile in this tumor type, but none are Phase 3 RCTs and TFDA/Medsafe safety documentation is currently a blocking data gap.
To proceed, the following is needed:
- TFDA/Medsafe package insert with warnings, contraindications, and DDI data (currently Blocking data gap)
- Confirmed mechanism of action data from DrugBank (currently High-severity data gap)
- New Zealand regulatory filing/market status confirmation, since the drug is currently unmarketed
- Classification/relevance grading of the pending clinical trials and literature (currently marked "pending" in the Evidence Pack)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.